Bruker Corporation (NASDAQ:BRKR) – Jefferies Group increased their Q3 2018 earnings per share estimates for Bruker Corporation in a research note issued to investors on Thursday. Jefferies Group analyst B. Couillard now anticipates that the medical research company will post earnings per share of $0.33 for the quarter, up from their prior forecast of $0.32. Jefferies Group also issued estimates for Bruker Corporation’s Q4 2018 earnings at $0.40 EPS, FY2018 earnings at $1.35 EPS and FY2019 earnings at $1.52 EPS.
BRKR has been the topic of a number of other reports. J P Morgan Chase & Co raised Bruker Corporation from an “underweight” rating to a “neutral” rating and set a $28.00 price target on the stock in a research note on Friday, November 3rd. Citigroup Inc. lifted their price target on Bruker Corporation from $29.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and issued a $24.00 price target on shares of Bruker Corporation in a research note on Tuesday, September 26th. Bank of America Corporation raised Bruker Corporation from an “underperform” rating to a “neutral” rating and set a $34.00 price target on the stock in a research note on Friday, November 3rd. Finally, BidaskClub raised Bruker Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $29.64.
Shares of Bruker Corporation (NASDAQ:BRKR) traded up $0.56 during trading hours on Monday, hitting $32.39. The stock had a trading volume of 657,700 shares, compared to its average volume of 632,791. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. The firm has a market capitalization of $5,130.00, a price-to-earnings ratio of 27.20, a PEG ratio of 2.69 and a beta of 1.05. Bruker Corporation has a 12-month low of $21.03 and a 12-month high of $35.16.
Bruker Corporation (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. The firm had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. Bruker Corporation had a return on equity of 25.83% and a net margin of 8.85%. The business’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 earnings per share.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 22nd. Shareholders of record on Monday, December 4th will be given a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.49%. Bruker Corporation’s dividend payout ratio is currently 17.02%.
In other Bruker Corporation news, VP Mark Munch sold 21,061 shares of Bruker Corporation stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total value of $631,198.17. Following the sale, the vice president now owns 60,524 shares in the company, valued at $1,813,904.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 35.20% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the business. Acrospire Investment Management LLC raised its position in Bruker Corporation by 496.1% in the second quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 3,185 shares during the period. SG Americas Securities LLC purchased a new stake in Bruker Corporation in the second quarter valued at $111,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Bruker Corporation by 11.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after buying an additional 467 shares during the period. Smithfield Trust Co. purchased a new stake in shares of Bruker Corporation in the 2nd quarter valued at $138,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Bruker Corporation by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after buying an additional 331 shares during the period. Institutional investors own 65.47% of the company’s stock.
About Bruker Corporation
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.